Antal Rohit Desai - Sep 10, 2024 Form 4 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
Director
Signature
/s/ Jonathan Stone, Attorney-in Fact for Mr. Antal Rohit Desai
Stock symbol
PRCT
Transactions as of
Sep 10, 2024
Transactions value $
-$9,375,595
Form type
4
Date filed
9/12/2024, 08:03 PM
Previous filing
Sep 5, 2024
Next filing
Nov 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRCT Common Stock Sale -$1.42M -18.7K -5.89% $75.78 299K Sep 10, 2024 By The 2:22 DNA Trust F1, F2
transaction PRCT Common Stock Sale -$1.36M -17.8K -5.96% $76.60 281K Sep 10, 2024 By The 2:22 DNA Trust F1, F3
transaction PRCT Common Stock Sale -$676K -8.9K -3.17% $75.90 272K Sep 11, 2024 By The 2:22 DNA Trust F1, F4
transaction PRCT Common Stock Sale -$376K -4.88K -1.79% $77.09 267K Sep 11, 2024 By The 2:22 DNA Trust F1, F5
transaction PRCT Common Stock Sale -$1.62M -20.7K -7.76% $78.12 247K Sep 11, 2024 By The 2:22 DNA Trust F1, F6
transaction PRCT Common Stock Sale -$329K -4.18K -1.7% $78.67 242K Sep 11, 2024 By The 2:22 DNA Trust F1, F7
transaction PRCT Common Stock Sale -$348K -4.46K -1.84% $78.00 238K Sep 12, 2024 By The 2:22 DNA Trust F1, F8
transaction PRCT Common Stock Sale -$183K -2.32K -0.97% $78.89 236K Sep 12, 2024 By The 2:22 DNA Trust F1, F9
transaction PRCT Common Stock Sale -$750K -9.4K -3.99% $79.78 226K Sep 12, 2024 By The 2:22 DNA Trust F1, F10
transaction PRCT Common Stock Sale -$2.31M -28.7K -12.69% $80.65 197K Sep 12, 2024 By The 2:22 DNA Trust F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 30, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.24 to $76.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.435 to $76.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.46 to $77.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.48 to $78.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.48 to $79.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $79.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.33 to $80.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.33 to $81.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.